complement growth long
read pacbio strateg
last night announc acquisit pacbio
billion cover strateg believ illumina
acquisit pacbio make lot sens market leader short-read
sequenc
base compani sequencing-by-synthesi sb
chemistri pacbio market leader long-read sequenc natur
complement short-read technolog area aspir enter
long time pacbio size market long-read sequenc
million estim almost quintupl
billion time combin could open interest opportun unifi
workflow unlock addit innov address unmet custom need
tradit measur acquisit multipl pacbio screen rich
could short-term dilut depend trajectori
pacbio product enhanc said believ commerci
opportun synergist platform justifi invest purchas price
repres around consensu revenu forecast given size
commerci infrastructur believ help de-risk aspect
commerci launch believ import factor watch abil
scale manufactur pacbio new chip compani express confid
worth note issu financ acquisit
avail resourc acquisit clearli better use capit sit
balanc sheet repurchas share given compani trade multipl frankli
given size repres fraction market cap base last night
close deal fund intern resourc also dont see lot
downsid acquisit final acquisit would resolv concern
potenti competit threat time pacbio
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
say elast
upgrad ow
strateg believ acquisit pacbio make lot sens
market leader short-read sequenc base compani
sequencing-by-synthesi sb chemistri sb short-read chemistri gener
million fragment dna read-length base pair bp
re-assembl form full view target area sb domin field
sequenc sever reason includ cost advantag abil scale high-
throughput platform gold-standard accuraci pacbio market leader long-
read sequenc natur complement short-read technolog
area aspir enter long time specif pacbio sequel
platform gener accur long-read averag provid
valuabl insight beyond short-read provid earli octob compani
launch new version softwar new consum reagent new smrt cell
note new sequenc chip accuraci simpl organ well
larger complex genom accuraci greater accuraci
averag pacbio size market long-read sequenc
million estim almost quintupl billion
note novaseq survey clearli demand interest
long-read sequenc technolog singl molecul sequenc
nanopor believ long-read supplement short-read technolog
work togeth differ advantag custom short-read technolog like
sequencing-by-synthesi sb chemistri highest qualiti consid
gold standard custom custom believ sb critic sequenc
technolog clinic set given abil detect singl nucleotid polymorph
copi number variat cnv indel underli human diseas said
long-read technolog provid advantag genom sequenc piec togeth
repetit area genom well non-human sampl plant given
brand custom relationship scale budget believ
compani potenti well posit penetr market time tabl
includ quot survey relat long-read technolog
valu custom see complement short-read
feedback custom demand long-rang sequenc
tradit measur acquisit multipl pacbio screen rich
could short-term dilut depend trajectori
pacbio product enhanc said believ commerci
opportun synergist platform justifi invest pay
billion acquisit pacbio per share repres premium
pacbio trade day volum price octob put per share price
perspect pacbio enter public market ipo price octob
purchas price discount compani all-tim high though
customerwhat view long-read sequenc a- care look pacbio sequel bionano sapphir ont also consid genet chromium machin far im concern realli look everyth year contempl buy machin ont market leader nanopor aggress market nanopor say noth secret compani even custom like us nanopor stupid b- bought nanopor gridiron leas bionano question structur variat short read technolog miss nanopor problem realli high error rate use lot sequenc gener perform error correct around tough find cancer find structur variat go see displac present time heard anyth nanopor center meet ceo noth murmur meet pretti mum thing readi let know cthe long read sequenc seemingli use posit price competit long time ont data human genom encourag project aggress increas yield gb price point data appl appl research give someth raw accuraci go one platform anoth today even total even per price would need addit sequenc price come could see interim situat data type use short accur read coupl nanopor long inaccur read could valuabl human genom nanopor thought neg month ago month ago start take much posit view theyv made lot progress make avail talk migrat clinic assay glong read realli get coupl novel area genom better understand long order structur genom potenti role structur human patholog diseas nanopor like higher capac per squar foot pacbio individu per base error rate still high make amend scaffold identif indel underli human diseas hhave look nanopor test think field today signific valu long read use pacbio sequel watch ont expect use pacbio nanopor provid much longer read end day error rate high ihav look nanopor yet technolog realli new chose given brand name industri leader captur bulk market share industri situat littl competitor need evalu pacbio system error rate still somewhat high want someth better error rate complex system data analysi complex librari run favor novaseq jhave ont minion pacbio sequel absolut critic long-read sequenc certain project genom world wait long time long-read sequenc use long-read short read necessari de novo genom scaffold bacteri genom scale promethion time kit accur yet need readi case someth chang still need use conjunct technolog barclay inc
larger share base overal valu current street consensu forecast purchas
price repres around revenu around forecast given size
commerci infrastructur believ help de-risk aspect
commerci launch believ import factor watch abil scale
manufactur pacbio new chip compani express confid final
worth note issu financ acquisit
avail resourc billion net cash sit compani balanc
sheet forecast almost million free cash flow
acquisit clearli better use capit sit balanc sheet
repurchas share given compani trade multipl frankli given size
repres fraction market cap base last night close
deal fund intern resourc also dont see lot downsid
acquisit final acquisit would resolv concern
potenti competit threat time pacbio
valuat analysi
manag believ regulatori barrier close
acquisit given compani compet differ market segment addit
note competit deal process
regulatori perspect ceo franci desouza note obvious work
next month work regulatori approv process countri
around world way think largest player
provid serv short-read market sequenc segment serv
complementari segment semest long-read player sens
uniqu qualifi segment play set
competitor short-read segment frankli realli play term
long-read segment look de novo sequenc exampl realli
well suit long-read player set player market
vibrant market view complementari add valu
custom us look player long-read segment pacbio
compet short-read segment compet long-read segment
relat competit asset ceo franci desouza note start say
look stay close happen long-read market
long time includ lesson space know
awar progress made market meant
know look pacbio deliv last month look
roadmap next month abl move move quickli
meant abl go process without
competit process knew space knew player knew
technolog achiev could achiev competit
process know touch said time right
us move
pac-bio obvious miss expect believ market
revenu million declin y/i came roughli street
expect million view miss like function delay
purchas ahead compani anticip technolog updat occur
earli octob specif octob compani launch enhanc
sequel platform includ new softwar updat consum new flow cell
smrt cell pac-bio languag addit given like better
posit evalu long-term prospect sequenc technolog
confid revenu shortfal indic long-term
demand pac-bio technolog long-read sequenc clearli
opportun dilig pac-bio busi awar expect go
fall short
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
